Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR.

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).